ird quarter financial results for the period ended September 30, 2009 and provide an update on recent corporate developments. To access the conference call, please dial 1-877-407-4018 (USA) or 1-201-689-8471 (international). A replay of the call will be available from 12:00 p.m. ET on November 16, 2009 until November 30, 2009. To access the replay, please dial 1-877-660-6853 (USA) or 1-201-612-7415 (international) and reference the account number 3055 and the access code 337401. A live audio webcast of the call will also be available from the Investors section on the corporate web site at http://www.sinovac.com
. A webcast replay can be accessed on the corporate website beginning November 16, 2009 and the replay will remain available for 30 days.
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's commercialized vaccine products include Healive® (hepatitis A), Bilive® (combined hepatitis A and B), Anflu® (seasonal influenza), Panflu(TM) (pandemic influenza (H5N1)), and PANFLU.1(TM) (pandemic influenza A (H1N1)). Sinovac is developing vaccines for enterovirus 71, universal pandemic influenza, pneumococcal infection, Japanese encephalitis, and human rabies. Its wholly owned subsidiary, Tangshan Yian, is conducting field trials for independently developed inactivated animal rabies vaccines.
Safe Harbor Statement
This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statem
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Related biology technology :1
|SOURCE Sinovac Biotech Co., Ltd.|
Copyright©2009 PR Newswire.
All rights reserved
. Sinovac Obtains Third H1N1 Vaccine Order from Chinese Central Government2
. Sinovac Receives Certificate of Approval to Distribute Panflu (H5N1) Vaccine in Hong Kong3
. Sinovac to Present at 2009 UBS Global Life Sciences Conference4
. Sinovac Obtains Lot Release Certificate for Its First Batch of H1N1 Vaccine5
. Sinovac Obtains Initial Order of H1N1 Vaccine from Chinese Central Government6
. Sinovac Obtains Production License for H1N1 Vaccine7
. Sinovac to Host Conference Call to Report 2009 Second Quarter Financial Results8
. Revised: Sinovac Provides Update on Clinical Trial for H1N1 Vaccine Trials9
. Sinovac Provides Update on Clinical Trial for H1N1 Vaccine Trials10
. Sinovac Initiates Dosing in Human Clinical Trial of Panflu for Pandemic Influenza A (H1N1)11
. Sinovac Adjourns 2008 Annual General Meeting